Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:AXSM NASDAQ:PRAX NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$77.16+3.0%$63.70$12.44▼$77.90$10.80B1.282.61 million shs206,626 shsAXSMAxsome Therapeutics$227.57+2.0%$171.73$96.09▼$234.29$11.66B0.59700,318 shs128,517 shsPRAXPraxis Precision Medicines$333.56+0.1%$318.06$35.18▼$356.00$9.30B2.76458,431 shs69,455 shsTARSTarsus Pharmaceuticals$65.40+0.6%$69.03$38.51▼$85.25$2.82B0.52558,540 shs40,356 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.16%+6.81%+22.78%+10.09%+435.98%AXSMAxsome Therapeutics+8.00%+20.57%+32.37%+20.22%+91.48%PRAXPraxis Precision Medicines+2.81%+3.54%+7.38%+9.88%+755.49%TARSTarsus Pharmaceuticals+2.23%+4.75%-7.24%+2.41%+35.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$77.16+3.0%$63.70$12.44▼$77.90$10.80B1.282.61 million shs206,626 shsAXSMAxsome Therapeutics$227.57+2.0%$171.73$96.09▼$234.29$11.66B0.59700,318 shs128,517 shsPRAXPraxis Precision Medicines$333.56+0.1%$318.06$35.18▼$356.00$9.30B2.76458,431 shs69,455 shsTARSTarsus Pharmaceuticals$65.40+0.6%$69.03$38.51▼$85.25$2.82B0.52558,540 shs40,356 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.16%+6.81%+22.78%+10.09%+435.98%AXSMAxsome Therapeutics+8.00%+20.57%+32.37%+20.22%+91.48%PRAXPraxis Precision Medicines+2.81%+3.54%+7.38%+9.88%+755.49%TARSTarsus Pharmaceuticals+2.23%+4.75%-7.24%+2.41%+35.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.83Moderate Buy$84.209.13% UpsideAXSMAxsome Therapeutics 2.90Moderate Buy$251.2610.41% UpsidePRAXPraxis Precision Medicines 3.00Buy$590.7877.11% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6738.63% UpsideCurrent Analyst Ratings BreakdownLatest TARS, ARWR, AXSM, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.005/5/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$217.00 ➝ $242.005/5/2026AXSMAxsome Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$228.00 ➝ $310.005/5/2026AXSMAxsome Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$241.00 ➝ $246.005/4/2026AXSMAxsome Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/4/2026AXSMAxsome Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$245.00 ➝ $260.005/4/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M13.03$0.12 per share639.78$3.64 per share21.20AXSMAxsome Therapeutics$638.50M18.33N/AN/A$1.75 per share130.04PRAXPraxis Precision Medicines$8.55M1,087.29N/AN/A$34.85 per share9.57TARSTarsus Pharmaceuticals$451.36M6.23N/AN/A$8.09 per share8.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M$1.5350.42N/AN/A18.54%35.64%13.61%5/7/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.69N/A40.78N/A-26.59%-246.90%-29.04%N/APRAXPraxis Precision Medicines-$303.27M-$13.46N/AN/AN/AN/A-58.74%-53.54%5/7/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.62N/A24.96N/A-14.72%-19.63%-12.70%5/6/2026 (Estimated)Latest TARS, ARWR, AXSM, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.1068N/AN/AN/A$73.84 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58N/AN/AN/A$0.10 millionN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.43N/AN/AN/A$150.30 millionN/A5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million2/23/2026Q4 2025AXSMAxsome Therapeutics-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million2/23/2026Q4 2025TARSTarsus Pharmaceuticals-$0.19-$0.20-$0.01-$0.20$144.56 million$151.67 million2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.293.383.38AXSMAxsome Therapeutics1.381.551.48PRAXPraxis Precision MedicinesN/A10.2210.22TARSTarsus Pharmaceuticals0.213.853.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%AXSMAxsome Therapeutics81.49%PRAXPraxis Precision Medicines67.84%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%AXSMAxsome Therapeutics20.60%PRAXPraxis Precision Medicines2.70%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.03 million134.99 millionOptionableAXSMAxsome Therapeutics38051.44 million40.84 millionOptionablePRAXPraxis Precision Medicines11027.87 million27.10 millionOptionableTARSTarsus Pharmaceuticals5043.02 million39.17 millionOptionableTARS, ARWR, AXSM, and PRAX HeadlinesRecent News About These CompaniesHC Wainwright Issues Pessimistic Outlook for TARS Earnings3 hours ago | marketbeat.comTarsus Pharmaceuticals, Inc. Q1 2026 earnings previewMay 5 at 10:40 PM | msn.comTarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC WainwrightMay 5 at 3:27 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC WainwrightMay 4 at 8:22 AM | marketbeat.comPictet Asset Management Holding SA Sells 36,069 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 4 at 5:33 AM | marketbeat.comD.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARSMay 3 at 4:02 AM | marketbeat.comJennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARSApril 30, 2026 | marketbeat.comTarsus Pharmaceuticals (TARS) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026April 29, 2026 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARSApril 27, 2026 | marketbeat.comCalamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARSApril 27, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Analysts at OppenheimerApril 24, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Position Increased by M&T Bank CorpApril 23, 2026 | marketbeat.comOrange County Drugmakers Boost Total Headcount by 3.5%April 21, 2026 | ocbj.comOTarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to "Hold" Rating by Wall Street ZenApril 18, 2026 | marketbeat.comWhy Tarsus Pharmaceuticals, Inc.’s (TARS) Stock Is Down 5.07%April 16, 2026 | aaii.comATarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.9% - Here's What HappenedApril 16, 2026 | marketbeat.comTarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline ProgressesApril 14, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by BrokeragesApril 13, 2026 | marketbeat.comCapricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARSApril 6, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN)April 4, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Going Dark: A Strange Buy Signal from the StarsBy Jeffrey Neal Johnson | April 8, 2026TARS, ARWR, AXSM, and PRAX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$77.16 +2.23 (+2.98%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Axsome Therapeutics NASDAQ:AXSM$226.43 +3.37 (+1.51%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Praxis Precision Medicines NASDAQ:PRAX$333.87 +0.57 (+0.17%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$65.40 +0.36 (+0.55%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
